Vext Science, Inc.

CNSX:VEXT Stock Report

Market Cap: CA$86.7m

Vext Science Valuation

Is VEXT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VEXT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CA$0.44
Fair Value
21.1% undervalued intrinsic discount
2
Number of Analysts

Below Fair Value: VEXT (CA$0.35) is trading below our estimate of fair value (CA$0.44)

Significantly Below Fair Value: VEXT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VEXT?

Key metric: As VEXT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VEXT. This is calculated by dividing VEXT's market cap by their current revenue.
What is VEXT's PS Ratio?
PS Ratio1.4x
SalesUS$44.15m
Market CapUS$61.72m

Price to Sales Ratio vs Peers

How does VEXT's PS Ratio compare to its peers?

The above table shows the PS ratio for VEXT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.7x
MDP Medexus Pharmaceuticals
0.6x11.62%CA$90.1m
PLTH Planet 13 Holdings
0.6x5.81%CA$102.5m
MTLC MTL Cannabis
0.9xn/aCA$72.2m
DB Decibel Cannabis
0.8x11.30%CA$75.0m
VEXT Vext Science
1.4x22.22%CA$86.7m

Price-To-Sales vs Peers: VEXT is expensive based on its Price-To-Sales Ratio (1.4x) compared to the peer average (0.7x).

Price to Sales Ratio vs Industry

How does VEXT's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

22 CompaniesPrice / SalesEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.03xn/aUS$13.16m
MRV Nuvo Pharmaceuticals
0.2xn/aUS$11.21m
RWB Red White & Bloom Brands
0.2xn/aUS$10.04m
AH Aleafia Health
0.2xn/aUS$5.93m
VEXT 1.4xIndustry Avg. 1.2xNo. of Companies22PS012345+
22 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VEXT is expensive based on its Price-To-Sales Ratio (1.4x) compared to the Canadian Pharmaceuticals industry average (1.2x).

Price to Sales Ratio vs Fair Ratio

What is VEXT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VEXT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ratio1.3x

Price-To-Sales vs Fair Ratio: VEXT is expensive based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VEXT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$0.34
CA$0.72
+110.14%
31.03%CA$0.95CA$0.50n/a2
Oct ’26CA$0.36
CA$0.72
+101.39%
31.03%CA$0.95CA$0.50n/a2
Sep ’26CA$0.28
CA$0.72
+163.64%
31.03%CA$0.95CA$0.50n/a2
Aug ’26CA$0.21
CA$0.72
+245.24%
31.03%CA$0.95CA$0.50n/a2
Jul ’26CA$0.17
CA$0.67
+304.04%
30.21%CA$0.95CA$0.50n/a3
Jun ’26CA$0.12
CA$0.67
+479.71%
30.21%CA$0.95CA$0.50n/a3
May ’26CA$0.13
CA$0.67
+433.34%
30.21%CA$0.95CA$0.50n/a3
Apr ’26CA$0.18
CA$0.67
+260.36%
30.21%CA$0.95CA$0.50n/a3
Mar ’26CA$0.15
CA$0.67
+344.45%
30.21%CA$0.95CA$0.50n/a3
Feb ’26CA$0.17
CA$0.67
+292.16%
30.21%CA$0.95CA$0.50n/a3
Jan ’26CA$0.17
CA$0.67
+304.04%
30.21%CA$0.95CA$0.50n/a3
Dec ’25CA$0.20
CA$0.67
+233.33%
30.21%CA$0.95CA$0.50n/a3
Nov ’25CA$0.18
CA$0.67
+260.36%
30.21%CA$0.95CA$0.50n/a3
Oct ’25CA$0.23
CA$0.60
+160.87%
18.00%CA$0.75CA$0.50CA$0.363
Sep ’25CA$0.23
CA$0.60
+160.87%
18.00%CA$0.75CA$0.50CA$0.283
Aug ’25CA$0.25
CA$0.63
+150.00%
12.00%CA$0.75CA$0.55CA$0.214
Jul ’25CA$0.23
CA$0.63
+175.36%
13.42%CA$0.75CA$0.55CA$0.173
Jun ’25CA$0.24
CA$0.63
+158.50%
13.42%CA$0.75CA$0.55CA$0.123
May ’25CA$0.32
CA$0.73
+132.80%
3.21%CA$0.75CA$0.70CA$0.133
Apr ’25CA$0.28
CA$0.73
+161.90%
3.21%CA$0.75CA$0.70CA$0.183
Mar ’25CA$0.29
CA$0.72
+145.76%
3.45%CA$0.75CA$0.70CA$0.152
Feb ’25CA$0.38
CA$0.72
+93.33%
3.45%CA$0.75CA$0.70CA$0.172
Jan ’25CA$0.29
CA$0.72
+150.00%
3.45%CA$0.75CA$0.70CA$0.172
Dec ’24CA$0.27
CA$0.75
+183.02%
5.44%CA$0.80CA$0.70CA$0.203
Nov ’24CA$0.28
CA$0.87
+204.09%
10.88%CA$1.00CA$0.80CA$0.183
Oct ’24CA$0.34
CA$0.87
+151.21%
10.88%CA$1.00CA$0.80CA$0.233
CA$0.72
Fair Value
52.4% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/15 16:16
End of Day Share Price 2025/10/15 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vext Science, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matt BottomleyCanaccord Genuity
Shaan MirCanaccord Genuity
Neal GilmerHaywood Securities Inc.